Skip to main content

Table 2 Patient stratification based on CAF circulating levels

From: Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial

Risk group Risk factors Criteria Median PFS (months) Median OS
(months)
Low 0 FGF-2 ≤ 950 pg/dL and
VEGF ≤ 19,000 pg/dL
38 67
Intermediate 1 FGF-2 > 950 pg/dL or
VEGF > 19,000 pg/dL
24 55
High 2 FGF-2 > 950 pg/dL and
VEGF > 19,000 pg/dL
15 37